Author Affiliations: Department of Urology and Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor.
The US Preventive Services Task Force recently issued a draft recommendation against prostate-specific antigen (PSA) screening for prostate cancer.1 After performing a rigorous review of the relevant empirical literature, the task force concluded with “moderate certainty” that the harms of PSA-based detection (eg, biopsy-related complications) and early intervention (eg, incontinence, erectile dysfunction) exceed the potential benefits. For this reason, the task force now proposes discouraging PSA screening among men who are free of symptoms suspicious for prostate cancer.
David C. Miller, Brent K. Hollenbeck. Missing the Mark on Prostate-Specific Antigen Screening. JAMA. 2011;306(24):2719–2720. doi:10.1001/jama.2011.1879